{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:12:53Z","timestamp":1792062773966,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"See manuscript for details","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Troponin T (TnT) is a well-known risk factor for negative outcome in hemodialysis (HD) patients, but little is known about variation over time, and the impact of clinical and dialysis specific factors. This study investigated the effect of angiotensin II receptor blockade (ARB), short and long-term variation in TnT and associations with clinical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this analysis based on the SAFIR-cohort (Clinical Trials ID: NCT00791830) 81 HD patients were randomized double-blind for placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200940) or angiotensin II receptor blocker (ARB) treatment (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200941) with irbesartan (150\u2013300\u2009mg) and followed for 12\u2009months with six serial measurements of TnT using a high-sensitivity assay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-four patients (67%) completed follow-up. Baseline TnT-medians (min-max) were (placebo\/ARB): 45(14\u2013295)\/46(10\u2013343) ng\/L. ARB-treatment did not significantly affect mean TnT-levels over the 12-month study period. Median week-to-week and one-year TnT-variation (5th\u201395th-percentile range) using all samples regardless of intervention were: 0(\u2212\u200914\u201310) ng\/L (week-to-week) and 3(\u2212\u200940\u201371) ng\/L (12\u2009months). Median TnT-amplitude, capturing the change from the lowest to the highest TnT-value observed during the one-year study period was 38% or 20.5\u2009ng\/L. Median ratios with 95% limits of agreement were: 1.00(0.73\u20131.37);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.92 (1\u2009week\/baseline;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200977) and 1.07(0.52\u20132.25);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.19 (12\u2009months\/baseline;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200954). Baseline TnT was positively correlated with diabetes, ultrafiltration volume, arterial stiffness, change in intradialytic total peripheral resistance and N-terminal pro b-type natriuretic peptide (NT-proBNP) and negatively correlated with hematocrit, residual renal function and change in intradialytic cardiac output. High baseline TnT was associated with a higher risk of admission and cardiovascular (CV) events during follow-up. Increase in TnT over time (\u0394TnT\u2009=\u200912-months-baseline) was significantly associated with increase in left ventricular (LV) mass and NT-proBNP and decrease in LV ejection fraction and late intradialytic stroke volume. \u0394TnT was not significantly associated with admissions, CV or intradialytic hypotensive events during follow-up. Admissions were significantly more likely with a high (TnT-amplitude&gt;\u200920.5\u2009ng\/L) than a low TnT-amplitude. Peaks in TnT were less frequent in aspirin-treated patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ARB-treatment had no significant effect on TnT-levels. Week-to-week variation was generally low, yet over 12\u2009months individual patients had considerable TnT fluctuations. Rise in TnT over time was significantly correlated with markers of cardiac deterioration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00791830\">NCT00791830<\/jats:ext-link>\n                      . Date of registration: November 17, 2008. EudraCT no: 2008\u2013001267-11.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-020-02103-1","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T09:03:06Z","timestamp":1603875786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["High-sensitivity Troponin T in hemodialysis patients: a randomized placebo-controlled sub-study investigating angiotensin-II-blockade, variation over time and associations with clinical outcome"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4917-1535","authenticated-orcid":false,"given":"Christian D.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista D.","family":"Kjaergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent L.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo M.","family":"Bibby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Jespersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens D.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"issue":"6","key":"2103_CR1","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1111\/j.1523-1755.2004.00657.x","volume":"65","author":"AK Cheung","year":"2004","unstructured":"Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int. 2004;65(6):2380\u20139.","journal-title":"Kidney Int"},{"issue":"13","key":"2103_CR2","first-page":"e356","volume":"115","author":"DA Morrow","year":"2007","unstructured":"Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National Academy of Clinical Biochemistry Laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115(13):e356\u201375.","journal-title":"Circulation"},{"issue":"22","key":"2103_CR3","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1161\/CIRCULATIONAHA.107.187397","volume":"116","author":"K Thygesen","year":"2007","unstructured":"Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation. 2007;116(22):2634\u201353.","journal-title":"Circulation"},{"issue":"1402","key":"2103_CR4","first-page":"97","volume":"127","author":"S Honneger Bloch","year":"2014","unstructured":"Honneger Bloch S, Honneger S, Semple D, Sidhu K, Stewart R, Pilmore H. Prognostic value and long-term variation of high sensitivity troponin T in clinically stable haemodialysis patients. N Z Med J. 2014;127(1402):97\u2013109.","journal-title":"N Z Med J"},{"issue":"7","key":"2103_CR5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/j.1440-1797.2012.01625.x","volume":"17","author":"TJ Pianta","year":"2012","unstructured":"Pianta TJ, Horvath AR, Ellis VM, Leonetti R, Moffat C, Josland EA, et al. Cardiac high-sensitivity troponin T measurement: a layer of complexity in managing haemodialysis patients. Nephrology (Carlton). 2012;17(7):636\u201341.","journal-title":"Nephrology (Carlton)"},{"issue":"7","key":"2103_CR6","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/ndt\/16.7.1452","volume":"16","author":"MC Iliou","year":"2001","unstructured":"Iliou MC, Fumeron C, Benoit MO, Tuppin P, Courvoisier CL, Calonge VM, et al. Factors associated with increased serum levels of cardiac troponins T and I in chronic haemodialysis patients: chronic Haemodialysis and new cardiac markers evaluation (CHANCE) study. Nephrol Dial Transplant. 2001;16(7):1452\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2103_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/ckj\/sfs122","volume":"6","author":"M Wolley","year":"2013","unstructured":"Wolley M, Stewart R, Curry E, Davidson J, White H, Pilmore H. Variation in and prognostic importance of troponin T measured using a high-sensitivity assay in clinically stable haemodialysis patients. Clin Kidney J. 2013;6(4):402\u20139.","journal-title":"Clin Kidney J"},{"issue":"23","key":"2103_CR8","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1161\/01.CIR.0000041254.30637.34","volume":"106","author":"FS Apple","year":"2002","unstructured":"Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106(23):2941\u20135.","journal-title":"Circulation"},{"issue":"3","key":"2103_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jama.290.3.353","volume":"290","author":"C deFilippi","year":"2003","unstructured":"deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003;290(3):353\u20139.","journal-title":"JAMA"},{"issue":"9","key":"2103_CR10","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1681\/ASN.2008010012","volume":"19","author":"AY Wang","year":"2008","unstructured":"Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008;19(9):1643\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2103_CR11","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2215\/CJN.00460112","volume":"7","author":"T Breidthardt","year":"2012","unstructured":"Breidthardt T, Burton JO, Odudu A, Eldehni MT, Jefferies HJ, McIntyre CW. Troponin T for the detection of dialysis-induced myocardial stunning in hemodialysis patients. Clin J Am Soc Nephrol. 2012;7(8):1285\u201392.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2103_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/ajkd.2002.33914","volume":"40","author":"F Mallamaci","year":"2002","unstructured":"Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2002;40(1):68\u201375.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2103_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1161\/01.CIR.0000109483.45211.8F","volume":"109","author":"JH Diris","year":"2004","unstructured":"Diris JH, Hackeng CM, Kooman JP, Pinto YM, Hermens WT, van Dieijen-Visser MP. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation. 2004;109(1):23\u20135.","journal-title":"Circulation"},{"issue":"12","key":"2103_CR14","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1373\/clinchem.2007.095679","volume":"53","author":"AH Wu","year":"2007","unstructured":"Wu AH, Jaffe AS, Apple FS, Jesse RL, Francis GL, Morrow DA, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007;53(12):2086\u201396.","journal-title":"Clin Chem"},{"issue":"7","key":"2103_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.7326\/M14-0743","volume":"161","author":"ED Michos","year":"2014","unstructured":"Michos ED, Wilson LM, Yeh HC, Berger Z, Suarez-Cuervo C, Stacy SR, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. Ann Intern Med. 2014;161(7):491\u2013501.","journal-title":"Ann Intern Med"},{"issue":"9311","key":"2103_CR16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G. de FU, et al. cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995\u20131003.","journal-title":"Lancet."},{"issue":"6","key":"2103_CR17","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1097\/00004872-200106000-00023","volume":"19","author":"K Malmqvist","year":"2001","unstructured":"Malmqvist K, Kahan T, Edner M, Held C, H\u00e4gg A, Lind L, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001;19(6):1167\u201376.","journal-title":"J Hypertens"},{"issue":"1","key":"2103_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MAJ.0b013e318249d387","volume":"345","author":"LY Yang","year":"2013","unstructured":"Yang LY, Ge X, Wang YL, Ma KL, Liu H, Zhang XL, et al. Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a meta-analysis. Am J Med Sci. 2013;345(1):1\u20139.","journal-title":"Am J Med Sci"},{"issue":"4","key":"2103_CR19","first-page":"A4602","volume":"60","author":"CD Peters","year":"2013","unstructured":"Peters CD, Kj\u00e6rgaard KD, Jespersen B, Christensen KL, Jensen JD. Renal and cardiovascular effects of irbesartan in dialysis patients - a randomized controlled trial protocol (SAFIR study). Dan Med J. 2013;60(4):A4602.","journal-title":"Dan Med J"},{"issue":"6","key":"2103_CR20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1053\/j.ajkd.2014.05.011","volume":"64","author":"KD Kjaergaard","year":"2014","unstructured":"Kjaergaard KD, Peters CD, Jespersen B, Tietze IN, Madsen JK, Pedersen BB, et al. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis. 2014;64(6):892\u2013901.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2103_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/ki.2014.69","volume":"86","author":"CD Peters","year":"2014","unstructured":"Peters CD, Kjaergaard KD, Jensen JD, Christensen KL, Strandhave C, Tietze IN, et al. No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients. Kidney Int. 2014;86(3):625\u201337.","journal-title":"Kidney Int"},{"issue":"6","key":"2103_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126882","volume":"10","author":"CD Peters","year":"2015","unstructured":"Peters CD, Kjaergaard KD, Jensen JD, Christensen KL, Strandhave C, Tietze IN, et al. Short and long-term effects of the angiotensin II receptor blocker Irbesartan on Intradialytic central hemodynamics: a randomized double-blind placebo-controlled one-year intervention trial (the SAFIR study). PLoS One. 2015;10(6):e0126882.","journal-title":"PLoS One"},{"issue":"6","key":"2103_CR23","first-page":"610","volume":"62","author":"DA Sica","year":"1997","unstructured":"Sica DA, Marino MR, Hammett JL, Ferreira I, Gehr TW, Ford NF. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. ClinPharmacolTher. 1997;62(6):610\u20138.","journal-title":"ClinPharmacolTher"},{"issue":"3","key":"2103_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/j.1552-4604.1998.tb04422.x","volume":"38","author":"MR Marino","year":"1998","unstructured":"Marino MR, Langenbacher K, Ford NF, Uderman HD. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol. 1998;38(3):246\u201355.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2103_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1373\/clinchem.2009.132654","volume":"56","author":"E Giannitsis","year":"2010","unstructured":"Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56(2):254\u201361.","journal-title":"Clin Chem"},{"issue":"6","key":"2103_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1373\/clinchem.2013.216978","volume":"60","author":"KM Aakre","year":"2014","unstructured":"Aakre KM, Roraas T, Petersen PH, Svarstad E, Sellevoll H, Skadberg O, et al. Weekly and 90-minute biological variations in cardiac troponin T and cardiac troponin I in hemodialysis patients and healthy controls. Clin Chem. 2014;60(6):838\u201347.","journal-title":"Clin Chem"},{"issue":"Pt 1","key":"2103_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/0004563214545116","volume":"52","author":"Z Corte","year":"2015","unstructured":"Corte Z, Garcia C, Venta R. Biological variation of cardiac troponin T in patients with end-stage renal disease and in healthy individuals. Ann Clin Biochem. 2015;52(Pt 1):53\u201360.","journal-title":"Ann Clin Biochem"},{"issue":"Pt 5","key":"2103_CR28","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/0004563215585877","volume":"52","author":"W Mbagaya","year":"2015","unstructured":"Mbagaya W, Luvai A, Lopez B. Biological variation of cardiac troponin in stable haemodialysis patients. Ann Clin Biochem. 2015;52(Pt 5):562\u20138.","journal-title":"Ann Clin Biochem"},{"issue":"12","key":"2103_CR29","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"RM Lang","year":"2005","unstructured":"Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440\u201363.","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"2103_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/hdi.12436","volume":"21","author":"CD Peters","year":"2017","unstructured":"Peters CD, Kjaergaard KD, Nielsen CH, Christensen KL, Bibby BM, Jensen JD, et al. Long-term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: a randomized double blind placebo controlled trial (SAFIR study). Hemodial Int. 2017;21(1):47\u201362.","journal-title":"Hemodial Int"},{"issue":"1","key":"2103_CR31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/ki.1995.22","volume":"47","author":"RN Foley","year":"1995","unstructured":"Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47(1):186\u201392.","journal-title":"Kidney Int"},{"issue":"2","key":"2103_CR32","doi-asserted-by":"publisher","first-page":"c126","DOI":"10.1159\/000163845","volume":"110","author":"A Takeda","year":"2008","unstructured":"Takeda A, Toda T, Iwamoto H, Watanabe K, Matsui N. Long-term evolution and changing associations of left ventricular hypertrophy after starting hemodialysis. Nephron ClinPract. 2008;110(2):c126\u2013c32.","journal-title":"Nephron ClinPract"},{"issue":"2","key":"2103_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/ki.1989.192","volume":"36","author":"JS Silberberg","year":"1989","unstructured":"Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36(2):286\u201390.","journal-title":"Kidney Int"},{"issue":"21","key":"2103_CR34","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","volume":"56","author":"G Cice","year":"2010","unstructured":"Cice G, Di Benedetto A, D'Isa S, D'Andrea A, Marcelli D, Gatti E, et al. Effects of Telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2010;56(21):1701\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2103_CR35","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1093\/ndt\/gfi125","volume":"20","author":"B Conway","year":"2005","unstructured":"Conway B, McLaughlin M, Sharpe P, Harty J. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis. Nephrol Dial Transplant. 2005;20(12):2759\u201364.","journal-title":"Nephrol Dial Transplant"},{"key":"2103_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/1874192400903010069","volume":"3","author":"FP Mongeon","year":"2009","unstructured":"Mongeon FP, Dorais M, Lorier JL, Froment D, Letendre E, Rinfret S. Effect of hemodialysis, coronary artery disease and diabetes on cardiac troponin T: a prospective survey over one year. Open Cardiovasc Med J. 2009;3:69\u201377.","journal-title":"Open Cardiovasc Med J"},{"issue":"6","key":"2103_CR37","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1159\/000485589","volume":"42","author":"MA Roberts","year":"2017","unstructured":"Roberts MA, Darssan D, Badve SV, Carroll RP, Fahim MA, Haluska BA, et al. Carvedilol and cardiac biomarkers in Dialysis patients: secondary analysis of a randomized controlled trial. Kidney Blood Press Res. 2017;42(6):1033\u201344.","journal-title":"Kidney Blood Press Res."},{"issue":"4","key":"2103_CR38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000079188","volume":"22","author":"SY Hung","year":"2004","unstructured":"Hung SY, Hung YM, Fang HC, Yeh JH, Hung GC, Wu CJ, et al. Cardiac troponin I and creatine kinase isoenzyme MB in patients with intradialytic hypotension. Blood Purif. 2004;22(4):338\u201343.","journal-title":"Blood Purif"},{"issue":"15","key":"2103_CR39","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.clinbiochem.2016.05.015","volume":"49","author":"S Badiou","year":"2016","unstructured":"Badiou S, Boudet A, Leray-Moragues H, Rodriguez A, Bargnoux AS, Dupuy AM, et al. Monthly reference change value of cardiac troponin in hemodialysis patients as a useful tool for long-term cardiovascular management. Clin Biochem. 2016;49(15):1195\u20138.","journal-title":"Clin Biochem"},{"key":"2103_CR40","volume-title":"O'Rourke and Charalambos Vlachopoulos. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles 6th Edition","author":"WW Nichols","year":"2011","unstructured":"Nichols WW, Michael F. O'Rourke and Charalambos Vlachopoulos. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles 6th Edition. London: Hodder Arnold; 2011."},{"issue":"6","key":"2103_CR41","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2215\/CJN.05200610","volume":"6","author":"HJ Jefferies","year":"2011","unstructured":"Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol. 2011;6(6):1326\u201332.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2103_CR42","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1681\/ASN.2008080824","volume":"20","author":"KE Chan","year":"2009","unstructured":"Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol. 2009;20(4):872\u201381.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2103_CR43","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1053\/j.ajkd.2007.07.007","volume":"50","author":"J Ethier","year":"2007","unstructured":"Ethier J, Bragg-Gresham JL, Piera L, Akizawa T, Asano Y, Mason N, et al. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2007;50(4):602\u201311.","journal-title":"Am J Kidney Dis"},{"key":"2103_CR44","volume":"2","author":"SC Palmer","year":"2013","unstructured":"Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2013;2:CD008834.","journal-title":"Cochrane Database Syst Rev"},{"key":"2103_CR45","unstructured":"KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients \n                  http:\/\/www.kidney.org\/professionals\/KDOQI\/guidelines_commentaries.cfm\n                  \n                . Accesed 2 Jan 2020."},{"issue":"2","key":"2103_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000063515","volume":"25","author":"A Tisl\u00e9r","year":"2002","unstructured":"Tisl\u00e9r A, Ak\u00f3csi K, H\u00e1rshegyi I, Varga G, Ferenczi S, Grosz M, et al. Comparison of dialysis and clinical characteristics of patients with frequent and occasional hemodialysis-associated hypotension. Kidney Blood Press Res. 2002;25(2):97\u2013102.","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"2103_CR47","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/j.1523-1755.2004.00812.x","volume":"66","author":"T Shoji","year":"2004","unstructured":"Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004;66(3):1212\u201320.","journal-title":"Kidney Int"},{"issue":"6","key":"2103_CR48","first-page":"1056","volume":"43","author":"H Suzuki","year":"2004","unstructured":"Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. AmJKidney Dis. 2004;43(6):1056\u201364.","journal-title":"AmJKidney Dis"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02103-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-020-02103-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02103-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T01:05:12Z","timestamp":1604106312000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-02103-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-02103-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.21910\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,28]]},"assertion":[{"value":"6 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with good clinical practice (GCP) and the ethical standards described in the Helsinki Declaration. All participating sites were monitored by a local independent GCP-Unit. Written informed consent was obtained from all participants. The Central Denmark Region Committees on Biomedical Research Ethics, the Danish Health and Medicines Authority, and the Danish Data Protection Agency approved the study.\n                      \n                      Identifier:\n                      \n                      EudraCT no: 2008\u2013001267-11.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication is not applicable to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Bibby reports personal fees from Kidney International and Kidney International Reports although not related to this paper. Besides funding sources, the other authors have declared that no competing interests exist.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}